| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02087661 |
| P698 | PubMed publication ID | 7525168 |
| P50 | author | Pierre Bedossa | Q42979649 |
| Thierry Poynard | Q43252014 | ||
| P2093 | author name string | J C Chaput | |
| S Naveau | |||
| C Benattar | |||
| P2860 | cites work | Measurement of proteins with the Behring Nephelometer. A multicentre evaluation | Q35855175 |
| Effects of cytokines on the liver | Q37642891 | ||
| Serum proteins in diseases of the liver | Q39352069 | ||
| Physical and chemical properties of human plasma β2-macroglobulin | Q39505132 | ||
| Radioimmunoassay for type III procollagen peptide and its application to human liver disease | Q39711497 | ||
| Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor | Q41343795 | ||
| A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis | Q43647769 | ||
| A simple biological index for detection of alcoholic liver disease in drinkers | Q45106831 | ||
| Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients | Q57783019 | ||
| Detection of fibronectin receptor in sera: Its clinical significance as a parameter of hepatic fibrosis | Q67901362 | ||
| Ito-cell gene expression and collagen regulation | Q68693251 | ||
| Cell types involved in collagen and fibronectin production in normal and fibrotic human liver | Q68865420 | ||
| Cultured Ito cells of rat liver express the alpha 2-macroglobulin gene | Q69007590 | ||
| Synthesis and secretion of alpha 2-macroglobulin by human hepatocytes in culture | Q69055506 | ||
| Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease | Q69179738 | ||
| Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients | Q69261733 | ||
| Apolipoprotein AI and alcoholic liver disease | Q70316026 | ||
| Quantitative immunoelectrophoresis of serum proteins in cryptogenic cirrhosis, alcoholic cirrhosis and active chronic hepatitis | Q70405820 | ||
| Sensitive radioimmunoassays for 7 S collagen and laminin: Application to serum and tissue studies of basement membranes | Q70932325 | ||
| [Abnormalities of ten plasma proteins in alcoholic liver disease (author's transl)] | Q71398207 | ||
| Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay | Q71585106 | ||
| A kinetic photometric method for serum gamma-glutamyl transpeptidase | Q72359596 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 2426-2432 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest | |
| P478 | volume | 39 |
| Q35575885 | "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. |
| Q30476922 | A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation |
| Q41972577 | A new index for non-invasive assessment of liver fibrosis |
| Q46827711 | A novel panel of blood markers to assess the degree of liver fibrosis |
| Q33490839 | A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease |
| Q37014721 | Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats |
| Q42734827 | Assessing liver fibrosis with serum marker models |
| Q45737816 | Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study |
| Q45259878 | Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease |
| Q36990696 | Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality |
| Q46419710 | Body fat distribution and risk factors for fibrosis in patients with alcoholic liver disease |
| Q59352860 | Caractéristiques et interprétation des tests sanguins de fibrose hépatique |
| Q26773289 | Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage |
| Q42196088 | Clinical Utility of Biomarkers of Liver Fibrosis |
| Q54962508 | Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy. |
| Q36496783 | Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis |
| Q39840925 | Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. |
| Q34893571 | Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease |
| Q43838210 | Early liver dysfunction in schistosomiasis. |
| Q37214588 | Effective use of FibroTest to generate decision trees in hepatitis C. |
| Q30449245 | Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study |
| Q29417076 | Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease |
| Q37210696 | GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics |
| Q52901959 | Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. |
| Q39210299 | Invasive and non-invasive assessment of portal hypertension. |
| Q38227839 | Liver fibrosis markers in alcoholic liver disease |
| Q47122280 | Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression |
| Q39592413 | Modification of mouse A2M B (620-792) and A2M N (168-230) by malondialdehyde and acetaldehyde attenuates the proteinase and TGF-β1 binding ability of A2MB. |
| Q26744631 | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
| Q42406716 | Non-invasive assessment of liver fibrosis |
| Q26780258 | Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. |
| Q36394872 | Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched |
| Q59050387 | Noninvasive Biomarkers of Liver Fibrosis: An Overview |
| Q83258968 | Noninvasive assessment of liver fibrosis |
| Q51545030 | Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. |
| Q36382285 | Noninvasive measures of liver fibrosis |
| Q33632731 | Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. |
| Q63379392 | Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease |
| Q58622804 | Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B |
| Q46827687 | Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model |
| Q42122494 | Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection |
| Q28365937 | Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C |
| Q39251941 | Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis |
| Q47816028 | Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. |
| Q36180551 | Relationship between clinical and pathologic findings in patients with chronic liver diseases |
| Q42855705 | Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis |
| Q78508417 | Serum hyaluronic acid as a comprehensive marker to assess severity of liver disease in schistosomiasis |
| Q30864670 | Study of transactivating effect of pre-S2 protein of hepatitis B virus and cloning of genes transactivated by pre-S2 protein with suppression subtractive hybridization |
| Q82812170 | The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis |
| Q73298618 | Thrombocytemia as a predictor of portal hypertension in schistosomiasis |
| Q73483388 | Transforming growth factor-β-induced collagen synthesis by human liver myofibroblasts is inhibited by α2-macroglobulin |
| Q33565557 | Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease |
| Q85855133 | [Serological markers of fibrosis] |
Search more.